Nature Reviews Cardiology最新文献_第3页

Apolipoprotein B100 revisited 载脂蛋白B100重测

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-04-10 DOI: 10.1038/s41569-025-01155-w

Mia S. Manojlovic, Melaku Taye Amogne

引用次数: 0

Primordial prevention of cardiovascular disease 从根本上预防心血管疾病

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-04-08 DOI: 10.1038/s41569-025-01153-y

Hooi Min Lim

引用次数: 0

Molecular gatekeepers of endogenous adult mammalian cardiomyocyte proliferation 内源性成年哺乳动物心肌细胞增殖的分子看门人

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-04-07 DOI: 10.1038/s41569-025-01145-y

Tim Koopmans, Eva van Rooij

{"title":"Molecular gatekeepers of endogenous adult mammalian cardiomyocyte proliferation","authors":"Tim Koopmans, Eva van Rooij","doi":"10.1038/s41569-025-01145-y","DOIUrl":"https://doi.org/10.1038/s41569-025-01145-y","url":null,"abstract":"Irreversible cardiac fibrosis, cardiomyocyte death and chronic cardiac dysfunction after myocardial infarction pose a substantial global health-care challenge, with no curative treatments available. To regenerate the injured heart, cardiomyocytes must proliferate to replace lost myocardial tissue — a capability that adult mammals have largely forfeited to adapt to the demanding conditions of life. Using various preclinical models, our understanding of cardiomyocyte proliferation has progressed remarkably, leading to the successful reactivation of cell cycle induction in adult animals, with functional recovery after cardiac injury. Central to this success is the targeting of key pathways and structures that drive cardiomyocyte maturation after birth — nucleation and ploidy, sarcomere structure, developmental signalling, chromatin and epigenetic regulation, the microenvironment and metabolic maturation — forming a complex regulatory framework that allows efficient cellular contraction but restricts cardiomyocyte proliferation. In this Review, we explore the molecular pathways underlying these core mechanisms and how their manipulation can reactivate the cell cycle in cardiomyocytes, potentially contributing to cardiac repair.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"16 1","pages":""},"PeriodicalIF":49.6,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A turning point in cardiac remodelling in obesity 肥胖症中心脏重构的转折点

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-04-07 DOI: 10.1038/s41569-025-01154-x

Mariella R. Huaman, Carlos J. Toro-Huamanchumo

引用次数: 0

Preserving the future of heart transplantation 保护心脏移植的未来

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-04-04 DOI: 10.1038/s41569-025-01146-x

David M. Kaye, David C. McGiffin

引用次数: 0

Tunnelling nanotube-like structures facilitate cell–cell communication during heart development 隧道纳米管样结构促进了心脏发育过程中细胞间的通信

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-04-02 DOI: 10.1038/s41569-025-01151-0

Karina Huynh

引用次数: 0

Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target 克隆造血在心血管疾病中的预后作用和新的治疗靶点

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-04-02 DOI: 10.1038/s41569-025-01148-9

Art Schuermans, Michael C. Honigberg

{"title":"Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target","authors":"Art Schuermans, Michael C. Honigberg","doi":"10.1038/s41569-025-01148-9","DOIUrl":"https://doi.org/10.1038/s41569-025-01148-9","url":null,"abstract":"Clonal haematopoiesis is the clonal expansion of blood stem cells with acquired mutations. Clonal haematopoiesis of indeterminate potential (CHIP), traditionally defined as clonal haematopoiesis driven by a pre-leukaemic mutation in at least 2% of sequenced alleles, affects 10–20% of individuals aged >70 years. Although CHIP is considered a precursor condition for haematological malignancies, population-based data suggest that the majority of CHIP-associated mortality is attributable to non-malignant conditions, such as cardiovascular disease. Observational human studies have shown that CHIP is a strong and independent predictor of the onset and progression of atherosclerotic cardiovascular disease, heart failure and arrhythmia. In addition, findings from animal experiments suggest that CHIP is causally involved in these diseases and might be a risk factor that can be targeted with therapeutics. As our understanding of the cardiovascular implications of CHIP and other types of clonal haematopoiesis rapidly expands, it has become increasingly clear that clonal haematopoiesis subtypes have substantial heterogeneity with respect to magnitude of effect and underlying mechanisms for different cardiovascular diseases. In this Review, we discuss clonal haematopoiesis as a prognostic factor for numerous cardiovascular diseases, highlight its potential as a therapeutic target and propose a potential role for CHIP in cardiovascular precision medicine.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"183 1","pages":""},"PeriodicalIF":49.6,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism 因子XI抑制剂用于预防和治疗静脉和动脉血栓栓塞

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-03-31 DOI: 10.1038/s41569-025-01144-z

Davide Capodanno, John H. Alexander, M. Cecilia Bahit, John W. Eikelboom, C. Michael Gibson, Shaun G. Goodman, Vijay Kunadian, Gregory Y. H. Lip, Renato D. Lopes, Roxana Mehran, Shamir R. Mehta, Manesh R. Patel, Jonathan P. Piccini, Sunil V. Rao, Christian T. Ruff, P. Gabriel Steg, Jeffrey I. Weitz, Dominick J. Angiolillo

{"title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","authors":"Davide Capodanno, John H. Alexander, M. Cecilia Bahit, John W. Eikelboom, C. Michael Gibson, Shaun G. Goodman, Vijay Kunadian, Gregory Y. H. Lip, Renato D. Lopes, Roxana Mehran, Shamir R. Mehta, Manesh R. Patel, Jonathan P. Piccini, Sunil V. Rao, Christian T. Ruff, P. Gabriel Steg, Jeffrey I. Weitz, Dominick J. Angiolillo","doi":"10.1038/s41569-025-01144-z","DOIUrl":"https://doi.org/10.1038/s41569-025-01144-z","url":null,"abstract":"Therapeutic anticoagulation is essential to prevent and treat venous and arterial thromboembolism. The available agents target coagulation factors involved in thrombus formation but are associated with an increased risk of bleeding. Factor XI plays a minor role in haemostasis but contributes substantially to thrombus expansion, making it an attractive target to mitigate bleeding while maintaining antithrombotic efficacy. Various novel inhibitors, including antisense oligonucleotides, monoclonal antibodies and small molecules, have been developed. Phase II trials in orthopaedic surgery showed dose-dependent reductions in venous thromboembolism without significantly increasing bleeding compared with enoxaparin. In the first phase III trial of a small-molecule inhibitor of activated factor XI in patients with atrial fibrillation, asundexian was associated with a reduction in bleeding but also a higher risk of stroke, compared with apixaban. Factor XI inhibitors appear safe and hold promise for secondary prevention in myocardial infarction and ischaemic stroke, with ongoing phase III trials assessing their broader efficacy and safety. This Review discusses the rationale, pharmacology, evidence and future directions of factor XI inhibitors across various clinical settings.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"5 1","pages":""},"PeriodicalIF":49.6,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Scientific journey from PSCK9 discovery in familial hypercholesterolaemia 从家族性高胆固醇血症中发现PSCK9的科学之旅

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-03-28 DOI: 10.1038/s41569-025-01147-w

Marianne Abifadel

引用次数: 0

Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling 神经酰胺通过G蛋白偶联受体信号通路加重动脉粥样硬化

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-03-26 DOI: 10.1038/s41569-025-01149-8

Irene Fernández-Ruiz

引用次数: 0